- Home
- GILD vs PLD Comparison
GILD vs PLD Comparison
Compare GILD & PLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- PLD
- Stock Information
- Founded
- GILD 1987
- PLD 1983
- Country
- GILD United States
- PLD United States
- Employees
- GILD N/A
- PLD N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- PLD Real Estate Investment Trusts
- Sector
- GILD Health Care
- PLD Real Estate
- Exchange
- GILD Nasdaq
- PLD Nasdaq
- Market Cap
- GILD 113.0B
- PLD 103.1B
- IPO Year
- GILD 1992
- PLD 1994
- Fundamental
- Price
- GILD $91.84
- PLD $109.45
- Analyst Decision
- GILD Buy
- PLD Buy
- Analyst Count
- GILD 26
- PLD 17
- Target Price
- GILD $98.17
- PLD $129.41
- AVG Volume (30 Days)
- GILD 6.6M
- PLD 4.9M
- Earning Date
- GILD 02-11-2025
- PLD 01-21-2025
- Dividend Yield
- GILD 3.35%
- PLD 3.51%
- EPS Growth
- GILD N/A
- PLD 2.06
- EPS
- GILD 0.10
- PLD 3.31
- Revenue
- GILD $28,299,000,000.00
- PLD $8,239,209,999.00
- Revenue This Year
- GILD $6.50
- PLD N/A
- Revenue Next Year
- GILD $0.36
- PLD $7.44
- P/E Ratio
- GILD $908.39
- PLD $33.07
- Revenue Growth
- GILD 3.31
- PLD 0.81
- 52 Week Low
- GILD $62.07
- PLD $100.82
- 52 Week High
- GILD $98.90
- PLD $135.76
- Technical
- Relative Strength Index (RSI)
- GILD 51.58
- PLD 53.33
- Support Level
- GILD $90.82
- PLD $103.23
- Resistance Level
- GILD $93.07
- PLD $112.00
- Average True Range (ATR)
- GILD 1.54
- PLD 2.48
- MACD
- GILD -0.03
- PLD 0.91
- Stochastic Oscillator
- GILD 56.28
- PLD 70.92
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.2 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.